GE Healthcare Inks Biopharmaceutical Purification Collaboration With BAC
Firms to develop new affinity chromatography media.!--h2>
GE Healthcare and the Bio Affinity Company (BAC) entered into an association agreement in the affinity ligand and chromatographic media area. “This collaboration will allow GE to expand it’s current range of ligand technologies and libraries, which will enable it to develop more efficient purification processes for it’s customers in biopharmaceutical manufacturing,” says Ann O’Hara, general manager of bioprocess for GE Healthcare.
Under the terms of the agreement, the two companies report that they will develop new affinity chromatography media for human antibodies and adeno-associated virus (AAV) viral vector purification. GE expects the first products to be commercially available in 2007 through GE Healthcare’s Custom Designed Media business.